Patents Assigned to Syntex (U.S.A.)
  • Patent number: 6979693
    Abstract: The present invention relates to certain pyrazole derivatives of Formula (I): that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: December 27, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: David Michael Goldstein, Sharada Shenvi Labadie, David Mark Rotstein, Eric Brian Sjogren, Francisco Xavier Talamas
  • Patent number: 6967093
    Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: November 22, 2005
    Assignees: The Regents of the University of California, Syntex (U.S.A) LLC
    Inventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
  • Patent number: 6951918
    Abstract: This invention relates to compounds of Formula (I) wherein R1-R7, A, Z and n are as described in the Summary of the Invention that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for their preparation.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: October 4, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Sharon Marie Dankwardt, Harold Edgar Van Wart, Keith Adrian Murray Walker
  • Patent number: 6933142
    Abstract: Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of HEC-GLCNAC6ST or KSGal6ST, or homologues thereof.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: August 23, 2005
    Assignees: The Regents of the University of California, Syntex (USA), LLC
    Inventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
  • Patent number: 6903086
    Abstract: This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein G1 is selected from the group consisting of a, b1 and b2, and A and G2 are as defined in the specification; or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: June 7, 2005
    Assignee: SYNTEX (U.S.A.) LLC
    Inventors: Francisco Javier Lopez-Tapia, Dov Nitzan, Counde O'Yang
  • Patent number: 6900220
    Abstract: This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X—Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: May 31, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Cyrus Kephra Becker, Joan Marie Caroon, Chris Richard Melville, Fernando Padilla, Jürg Roland Pfister, Xiaoming Zhang
  • Patent number: 6900336
    Abstract: This invention relates to compounds which are generally EP4 receptor agonists and which are represented by Formula I: wherein A is a —CH2—CH2—, or —CH?CH—; B is absent, an aryl, or heteroaryl group; R1 is alkyl, alkenyl, alkynyl, cycloalkylalkyl, heterocyclylalkyl, aryl, arylalkyl or heteroaryl, when B is aryl or heteroaryl and R3, R4, R5 and R6 are not simultaneously hydrogen, or R1 is heterocyclylalkyl, aryl, or heteroaryl when B is absent and R3, R4, R5 and R6 are simultaneously hydrogen; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 31, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Todd Richard Elworthy, Tara Mirzadegan, Michael Garret Roepel, David Bernard Smith, Keith Adrian Walker
  • Patent number: 6893842
    Abstract: The invention provides TCCV-1 or TCCV-2 from human, reagents related thereto including polynucleotides encoding TCCV-1 or TCCV-2, purified polypeptides, and specific antibodies. Methods of making and using these reagents, in particular, methods for screening compounds which modulate TCCV-1 or TCCV-2 activity are provided. Also provided are methods of diagnosis and kits.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: May 17, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Paul Shartzer Dietrich, Joseph Gerrard McGivern
  • Patent number: 6872744
    Abstract: This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: wherein A is a —CH2—, —O—, —S—, or —S(O)—; and the other substituents are as defined in the specification; or individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: March 29, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Chris Allen Broka, Jeffrey Allen Campbell
  • Patent number: 6864266
    Abstract: This invention relates to the (R)-isomers of compounds which are generally muscarinic receptor antagonists and which are represented by Formula I: wherein p, R1, R2, R3 and A are as defined in the specification, or individual isomers, racemic or non-racemic mixtures of isomers, or acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use and preparation as therapeutic drugs.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: March 8, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Christine E. Brotherton-Pleiss, Ann Marie Madera, Robert James Weikert
  • Patent number: 6861423
    Abstract: Disorders mediated by p38 kinase inhibitors are treated with compounds of the formula: or salts thereof, wherein: R1 is hydrogen or alkyl; R2 is substituted cycloalkyl, heterosubstituted cycloalkyl, helcroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl-alkly, heterocyclyl, heterocyclyl spiro cycloalkyl, aralkoxy, alkoxy, -alkylene-S(O)n-alkyl (where is 1 or 2) or —SO2Ar2; R3 is hydrogen, amino, monoalkylamino, dialkylamino, acylamino, —NR8—C(?O)—Rb (where Ra is hydrogen or alkyl and Rh is heterocyclyl or heteroalkyl), alkyl, cycloalkyl, phthalimidoalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(O) R (where R is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl; and each of Ar1 and Ar2 is independently aryl.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: March 1, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Jian Jeffrey Chen, James Patrick Dunn, David Michael Goldstein, Julie Anne Lim
  • Patent number: 6852518
    Abstract: Novel glycosylsulfotransferases (GST-4?, GST-4?, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4?, GST-4?, and GST-6.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: February 8, 2005
    Assignees: The Regents of the University of California, Syntex (U.S.A.) LLC
    Inventors: Steven D. Rosen, Jin Kyu Lee, Stefan Hemmerich
  • Patent number: 6852726
    Abstract: This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: wherein X is —S(O)n— or —C(O)—, A is C1-6alkyl, aryl, heteroaryl, hydroxyalkyl, or —(CH2)p—NRaRb, and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: February 8, 2005
    Assignee: Syntex LLC
    Inventors: Robert Greenhouse, Saul Jaime-Figueroa, Lubica Raptova
  • Patent number: 6849657
    Abstract: This invention relates to 8-aza prostanoid analogs which are generally EP4 receptor agonists and are represented by Formula I: wherein Q, B, X, J, Z, A and R1-R6 are as defined, their synthesis and use for treatment of osteoporosis and increasing bone density.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: February 1, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Todd Richard Elworthy, Michael Garret Roepel, David Bernard Smith
  • Patent number: 6846834
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: January 25, 2005
    Assignees: Amgen Inc., Syntex (U.S.A.) LLC
    Inventors: Michelle F. Browner, David L. Clark, Timothy D. Cushing, Xiaolin Hao, Ronald C. Hawley, Xiao He, Juan C. Jaen, Sharada S. Labadie, Marie-Louise Smith, Francisco X. Talamas, Nigel P. C. Walker, Marc Labelle
  • Patent number: 6844175
    Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: January 18, 2005
    Assignees: The Regents of the University of the California, Syntex (U.S.A.) INC
    Inventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
  • Patent number: 6844366
    Abstract: This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: January 18, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Roland Joseph Billledeau, Chris Allen Broka, Jeffrey Allen Campbell, Jian Jeffrey Chen, Sharon Marie Dankwardt, Nancy Delaet, Leslie Ann Robinson, Keith Adrian Murray Walker
  • Patent number: 6844466
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 18, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Paula Nanette Belloni, Denis John Kertesz, Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6838472
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 4, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6825202
    Abstract: This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula (I): wherein Ar, R1, R2, R3 or R4 are as defined in the specification, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: November 30, 2004
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Jacob Berger, Robin Douglas Clark, Shu-Hai Zhao